Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features

Clinical Sarcoma Research

Maria Debiec-Rychter²  Nils Mandahl⁸  Kristina Åström⁷  Henryk A Domanski⁴  Raf Sciot⁶  Angelo P Dei Tos¹  Pancras CW Hogendoorn^1,10  Marco Alberghini⁵  Nick Athanasou⁹  Roberto Tirabosco³  Judith VMG Bovée^1,10  Salvatore Romeo¹  Fredrik Mertens⁸ 

[1] Department of Pathology, Treviso Regional Hospital, Treviso, Italy;Center for Human Genetics, Catholic University of Leuven, Leuven, Belgium;Department of Pathology, Royal National Orthopaedic Hospital, London, UK;Department of Pathology, Lund University Hospital, Lund, Sweden;Department of Pathology, Rizzoli Orthopaedic Institute, Bologna, Italy;Department of Pathology, Catholic University of Leuven, Leuven, Belgium;Department of Pathology, Karolinska Hospital, Stockholm, Sweden;Department of Clinical Genetics, University and Regional Laboratories, Skåne University Hospital, Lund University, Lund, Sweden;Department of Pathology, Nuffield Orthopaedic Center, Oxford, UK;Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands

关键词: FUS;    EWSR1;    chromosome banding;    Malignant fibrous histiocytoma of bone;   

Others  :  863018
DOI  :  10.1186/2045-3329-1-10

 received in 2011-09-06, accepted in 2011-10-13,  发布年份 2011

【 摘 要 】

Background

The diagnostic entity malignant fibrous histiocytoma (MFH) of bone is, like its soft tissue counterpart, likely to be a misnomer, encompassing a variety of poorly differentiated sarcomas. When reviewing a series of 57 so-called MFH of bone within the framework of the EuroBoNeT consortium according to up-to-date criteria and ancillary immunohistochemistry, a fourth of all tumors were reclassified and subtyped.

Methods

In the present study, the cytogenetic data on 11 of these tumors (three myoepithelioma-like sarcomas, two leiomyosarcomas, one undifferentiated pleomorphic sarcoma with incomplete myogenic differentiation, two undifferentiated pleomorphic sarcomas, one osteosarcoma, one spindle cell sarcoma, and one unclassifiable biphasic sarcoma) are presented.

Results

All tumors were high-grade lesions and showed very complex karyotypes. Neither the overall pattern (ploidy level, degree of complexity) nor specific cytogenetic features distinguished any of the subtypes. The subgroup of myoepithelioma-like sarcomas was further investigated with regard to the status of the EWSR1 and FUS loci; however, no rearrangement was found. Nor was any particular aberration that could differentiate any of the subtypes from osteosarcomas detected.

Conclusions

chromosome banding analysis is unlikely to reveal potential genotype-phenotype correlations between morphologic subtypes among so-called MFH of bone.

【 授权许可】

   
2011 Mertens et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Fletcher CDM: Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992, 16:213-228.
• [2]Fletcher CDM, Unni KK, Mertens F, Eds: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
• [3]Fletcher CDM, van den Berg E, Molenaar WM: Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:294-296.
• [4]Fletcher CDM, Gustafson P, Rydholm A, Willén H, Åkerman M: Clinicopathologic re-evaluation of 100 malignant fibrous histtiocytomas: prognostic relevance of subclassification. J Clin Oncol 2001, 19:3045-3050.
• [5]Steiner GC, Jundt G, Martignetti JA: Malignant fibrous histiocytoma of bone. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:294-296.
• [6]Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F: Rings, dicentrics, and telomeric association in histiocytomas. Cancer Genet Cytogenet 1988, 30:23-33.
• [7]Shaffer LG, Slovak ML, Campbell LJ: An International System for Human Cytogenetic Nomenclature (2009). Basel: Karger; 2009.
• [8]Taubert H, Berger D, Hinze R, Meye A, Würl P, Hogendoorn PCW, Holzhausen H-J, Schmidt H, Rath F-W: How is the mutational status for tumor suppressors p53 and p16INK4A in MFH of the bone? Cancer Lett 1998, 123:147-151.
• [9]Tarkkanen M, Larramendy ML, Böhling T, Serra M, Hattinger CM, Kivioja A, Elomaa I, Picci P, Knuutila S: Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridization and c-MYC expression by immunohistochemistry. Eur J Cancer 2006, 42:1172-1180.
• [10]Bridge JA, Sanger WG, Neff JR, Hess MM: Cytogenetic findings in a primary malignant fibrous histiocytoma of bone and the lung metastasis. Pathology 1990, 22:16-19.
• [11]Örndal C, Mandahl N, Carlén B, Willén H, Wennerberg J, Heim S, Mitelman F: Near-haploid clones in a malignant fibrous histiocytoma. Cancer Genet Cytogenet 1992, 60:147-151.
• [12]Molenaar WM, van den Berg E, Veth RPH, Dijkhuizen T, de Vries EGE: Tumor progression in a giant cell type malignant fibrous histiocytoma of bone: clinical, radiologic, histologic, and cytogenetic evidence. Genes Chromosomes Cancer 1994, 10:66-70.
• [13]Walter TA, Weh H-J, Schlag PM, Zornig C, Hossfeld DK: Cytogenetic studies in malignant fibrous histiocytoma. Cancer Genet Cytogenet 1997, 94:131-134.
• [14]Antonescu CR, Zhang L, Chang N-E, Pawel BR, Travis W, Katabi N, Edelman M, Rosenberg AE, Nielsen GP, Dal Cin P, Fletcher CDM: EWSR1-POU5F1 fusion in soft tissue myoepthelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer 2010, 49:1114-1124.
• [15]Szuhai K, IJszenga M, de Jong D, Karseladze A, Tanke HJ, Hogendoorn PCW: The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res 2009, 15:2259-2268.
• [16]Carneiro A, Francis P, Bendahl PO, Fernebro J, Åkerman M, Fletcher CDM, Rydholm A, Borg Å, Nilbert M: Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest 2009, 89:668-675.